SEC Filings

AVEXIS, INC. filed this Form 424B5 on 01/18/2018
Entire Document

financial statements, including the notes to those financial statements, incorporated by reference in this prospectus.

  Year Ended December 31,  
  2013   2014   2015   2016  

Ratio of earnings to fixed charges(1)(2)

    N/A     N/A     N/A     N/A  

For purposes of computing the ratio of earnings to fixed charges, earnings consist of our net loss from continuing operations for the period plus fixed charges. We had no capitalized interest during any period. Fixed charges consist of interest expense and an estimate of the interest portion of rental expense. The ratio of earnings to fixed charges was less than one-to-one for each of the periods presented.

Earnings were insufficient to cover fixed charges by $2.2 million in 2013, $16.4 million in 2014, $38.5 million in 2015 and $83.0 million in 2016.


        We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Unless otherwise indicated in any prospectus supplement, we intend to use the net proceeds from the sale of the securities under this prospectus for general corporate purposes, which may include clinical trial and other research and development expenses, commercialization expenses, capital expenditures, working capital and general and administrative expenses, and potential acquisitions of or investments in businesses, products and technologies that complement our business, although we have no present commitments or agreements to make any such acquisitions or investments. We will set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing prospectus. Pending these uses, we intend to invest the net proceeds in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.


        As of the date of this prospectus, our amended and restated certificate of incorporation, or our restated certificate, authorizes us to issue 100,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. As of March 14, 2017, 27,739,724 shares of common stock were outstanding and no shares of preferred stock were outstanding.

        The following summary description of our capital stock is based on the provisions of our restated certificate, as well as our amended and restated bylaws, or our restated bylaws, and the applicable provisions of the Delaware General Corporation Law. This information is qualified entirely by reference to the applicable provisions of our certificate of incorporation, as amended, bylaws, as amended, and the Delaware General Corporation Law. For information on how to obtain copies of our certificate of incorporation, as amended, and bylaws, as amended, which are exhibits to the registration statement of which this prospectus is a part, see "Where You Can Find Additional Information."

Common Stock

Voting Rights

        Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Under our restated certificate and our amended and restated bylaws, or our restated bylaws, our stockholders do not have cumulative voting


© AveXis, Inc. All Rights Reserved.